Human randomized controlled trial

A fasting-mimicking diet in patients with mild-to-moderate Crohn’s disease: a randomized controlled trial

An open-label randomized trial in adults with mild-to-moderate Crohn's disease.

Nat Med, 2026. Kulkarni C, et al.

Funding and competing interests (as published with the paper): Competing interests: V.D.L. has equity interest in L-Nutra and has filed patents related to the FMD. V.D.L. does not receive consulting fees from L-Nutra and has committed his shares of the company to charitable organizations. The authors declare no competing interests.

Read the full study

Opens the journal or PubMed page in a new tab. Some journals require a subscription.

Study type
Human clinical trial (randomized, open-label)
Journal
Nat Med
Published
2026
Authors
Kulkarni C, et al.
DOI
10.1038/s41591-025-04173-w
PubMed ID
41530382

Summary

Adults with mild-to-moderate Crohn's disease were randomly assigned, in an open-label trial, either to follow a Fasting Mimicking Diet (FMD) for five consecutive days a month for three months while eating their regular diet on other days, or to continue their baseline diet throughout. The primary outcome was clinical response, defined as a fall of at least 70 points in the Crohn's Disease Activity Index or an index value of 150 or below after the third diet cycle. Fecal calprotectin, plasma metabolites and gene expression in blood mononuclear cells were also measured.

The authors reported that 69.2% of the diet group and 43.8% of the control group met the primary outcome of clinical response, and that 64.6% of the diet group and 37.5% of the control group reached the secondary outcome of clinical remission. They reported a fall from baseline in fecal calprotectin in the diet group and a rise in the control group. They reported that exploratory analyses found post-diet decreases in inflammatory lipid mediators and immune-effector transcripts. They state that the findings support further investigation of the diet as an adjunctive therapy in chronic inflammatory diseases.

This trial was open-label, so participants and investigators knew which diet was assigned, and the primary outcome is a symptom-based activity index that participant expectation can influence. It ran for three months, so it says nothing about longer use. The metabolite and gene expression analyses are labelled exploratory by the authors. Participants were patients with mild-to-moderate Crohn's disease, not a general wellness population, and the study does not evaluate Prolon directly.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.